1

DiaSorin

DiaSorin
Leadership team

Dr. Chen Menachem Even (Chief Commercial Officer, Sr. Corp. VP of Commercial Operations & Exec. Director)

Mr. Piergiorgio Pedron (Sr. Corp. VP, CFO & Corp. Accounting Documents Officer)

Products/ Services
Biotechnology, Health Diagnostics
Number of Employees
1,000 - 20,000
Headquarters
Saluggia, Piemonte, Italy
Established
1968
Company Registration
SEC CIK number: 0001856043
Net Income
100M - 500M
Revenue
Above - 1B
Social Media
Overview
Location
Summary

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

History

 

The origins of the company date back to 1968, when near on an initiative of Fiat and Montecatini, the "Sorin Biomedica" was founded by the "Società Ricerche Impianti Nucleari - Sorin". In 1997 American Standard acquired Sorin Biomedica, together with Immunonuclear Corporation . The two companies formed the Medical System Group of American Standard that later on came to include also Sienna Biotech, Inc DiaSorin became an independent Italian group in 2000, through a management buyout operation led by Carlo Rosa and Gustavo Denegri.The etymology of the name contains the acronym of Sorin, "Nuclear plant research company", the company established in the 1960s, and "Dia" which stands for Diagnostics. In 1997 Sorin decided to build upon the activities relating to in vitro diagnostics into a company that took on the name of DiaSorin Vercelli.

Mission

We are one of the world leaders in the laboratory diagnostics market, specializing in the segments of immunodiagnostics and molecular diagnostics.

Vision

We support clinical laboratory needs and activities, providing solutions that are reliable, innovative, fully automated and standardized.

Key Team

Mr. Riccardo Fava (Corp. VP of Communication & Investor Relations)

Mr. Ulisse Spada (Mang. of Corp. Legal Affairs Department)

Mr. Stefano Ronchi (Sr. Corp. VP of HR)

Mr. Fabrizio Bonelli (Chief Scientific Officer)

Mr. Ugo Gay (Sr. Corp. VP of Industrial Operations)

Mr. Angelo Rago (Pres of Luminex Corp.)

References
DiaSorin
Leadership team

Dr. Chen Menachem Even (Chief Commercial Officer, Sr. Corp. VP of Commercial Operations & Exec. Director)

Mr. Piergiorgio Pedron (Sr. Corp. VP, CFO & Corp. Accounting Documents Officer)

Products/ Services
Biotechnology, Health Diagnostics
Number of Employees
1,000 - 20,000
Headquarters
Saluggia, Piemonte, Italy
Established
1968
Company Registration
SEC CIK number: 0001856043
Net Income
100M - 500M
Revenue
Above - 1B
Social Media